Tanezumab
Based on 1 Customer Validation
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia.
For research use only. We do not sell to patients.
- Purity: 99.52%
- CAS No.: 880266-57-9
- Molecular Weight:145.44 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG2 kappa
Human
NGF/bNGF
Tanezumab (100 ng/mL, 48 h) decreases the expression of NGF proteins, inhibits the migration and invasion of cells MiaPaCa-2 and CFPAC-1[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MiaPaCa-2 and CFPAC-1
-
Concentration:100 ng/mL
-
Incubation Time:48 h
-
Result:Inhibited cell migration.
Tanezumab (2.5-5 mg/kg, sc, once a week for 4 weeks) exhibits anti-inflammatory and analgesic effects in rats Kashin-Beck Disease models[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MiaPaCa-2 xenograft mouse models[3]
-
Dosage:10 mg/kg
-
Administration:sc, once a day for 8 weeks
-
Result:Reduced the tumor volume and invasive nerve diameter.
Alleviated hindlimb dysfunction.
-
Animal Model:Sprague-Dawley rat Kashin-Beck Disease models[4]
-
Dosage:2.5-5 mg/kg
-
Administration:sc, once a week for 4 weeks
-
Result:Increased the paw withdrawal mechanical threshold (PWT) and thermal paw withdrawal latency (PWL).
Decreased serum TNF-α and IL-1β levels.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
-
Immobilized Beta-NGF Protein, Human, HEK293, HY-P7660 can bind Tanezumab. The EC50 for this effect is 5.218 ng/mL. -
Flow cytometric analysis of 1.5×106 SHSY5Y cells labeling Tanezumab (HY-P99221, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa Isotype Control (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 880266-57-9
-
Appearance Liquid
-
Molecular Weight 145.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Tanezumab]
-
Synonyms
RN-624; PF 4383119
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Evans M, et al. Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period. Auton Neurosci. 2019 May;218:51-53. [Content Brief]
[3]. Peng T, et al., Nerve Growth Factor (NGF) Encourages the Neuroinvasive Potential of Pancreatic Cancer Cells by Activating the Warburg Effect and Promoting Tumor Derived Exosomal miRNA-21 Expression. Oxid Med Cell Longev. 2022 Oct 15;2022:8445093. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)